Tanezumab in Osteoarthritis: Data Presented at OARSI Save
Pooled analyses of the tanezumab (a nerve growth factor inhibitor) phase 3 studies was presented at the 2015 Osteoarthritis Research Society International (OARSI) World Congress. Safety and efficacy data from 2,979 patients with moderate-to-severe hip or knee OA (25% had severe OA) is detailed in this report. Adverse events and withdrawals were equal to comparators but more than placebo. Neuropathic sensations were more common on the biologic (5.8%) compared to placebo (1.7%).